VISCOGLIOSI BROTHERS BID TO ACQUIRE BMP ASSETS (Orthopedics This Week)
Viscogliosi Brothers, LLC, the leading merchant banker in the global orthopedics industry, has made a bid to acquire the patent estate for an innovative line of bone morphogenic proteins (BMP) which originated at Wyeth, went to Pfizer and then eventually wound up at Bioventus, a global leader in orthobiologic solutions.
On July 23, Bioventus announced that it had entered into a definitive agreement to divest its BMP intellectual property portfolio to a new company formed by Viscogliosi Brothers, LLC (VB).
Bioventus had originally acquired the exclusive, worldwide license to the BMP portfolio of development programs and associated intellectual property from Pfizer, Inc., in 2013. The portfolio includes the next-generation BMP in development, as well as a BMP program for soft tissue indications.
The transaction, which is conditioned on a fund raise by VB, is expected to close in late Q3. When completed, Bioventus will receive an equity stake in the new VB company and will have an observational board seat.
No sale price was disclosed.
“Divesting the BMP program gives us the opportunity to increase the R&...
